Lifitegrast

Overview

Lifitegrast is a Lymphocyte Function-Associated Antigen-1 (LFA-1) antagonist. It is used for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins, thus lessening overall inflammatory responses. It was initially developed by SARcode Bioscience, which was acquired by Shire in 2013.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Inflammation / Immunology | Lymphocyte function-associated antigen 1(LFA-1)

Product Information

• Catalog No.: B0084-474974
• CAS No.: 1025967-78-5
• Molecular Formula: C29H24Cl2N2O7S
• Molecular Weight: 615.48
• Purity: >98%
• Storage: Store at -20°C
• Solubility: 10 mM in DMSO.

Source

Original product source